The emergence of new drugs for overactive bladder.

about

Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Urinary Incontinence in Older Adults: A Translational Research Agenda for a Complex Geriatric Syndrome.

P2860

Q47200622-D91D77DB-90B5-42AD-A05F-F8D158ABE0A5

P2860

The emergence of new drugs for overactive bladder.

Item

http://www.wikidata.org/entity/Q36407417

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

The emergence of new drugs for overactive bladder.

@ast

The emergence of new drugs for overactive bladder.

@en

type

Item

label

The emergence of new drugs for overactive bladder.

@ast

The emergence of new drugs for overactive bladder.

@en

prefLabel

The emergence of new drugs for overactive bladder.

@ast

The emergence of new drugs for overactive bladder.

@en

P1476

The emergence of new drugs for overactive bladder.

@en

P2093

Phillip P Smith

http://www.w3.org/2001/XMLSchema#string

Rebecca J McCrery

http://www.w3.org/2001/XMLSchema#string

Rodney A Appell

http://www.w3.org/2001/XMLSchema#string

P2860

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data

Regulation of calcium in salivary gland secretion.

Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.

Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia.

M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial.

Pharmacokinetics and safety of solifenacin succinate in healthy young men.

P304

125-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.11.1.125

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16503831

http://www.w3.org/2001/XMLSchema#string

The emergence of new drugs for overactive bladder.

about

P2860

P2860

The emergence of new drugs for overactive bladder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698